A compound called indole propionic acid, produced naturally by gut bacteria, improved blood sugar control and reduced cellular damage in diabetic rats by activating glucose-uptake pathways and boosting antioxidant defenses. According to Gram Research analysis, this finding suggests that enhancing beneficial gut bacteria could become a complementary diabetes management strategy, though human studies are still needed to confirm these results.
Researchers discovered that a natural compound produced by gut bacteria called indole propionic acid (IPA) may help people with diabetes control their blood sugar levels better. In a study using rats with diabetes, IPA improved how the body uses glucose, boosted the body’s natural defenses against damage, and activated important pathways that help cells absorb sugar. According to Gram Research analysis, this finding suggests that enhancing beneficial gut bacteria might offer a new way to manage diabetes alongside traditional treatments. The research opens doors to understanding how our gut microbiome influences metabolic health.
Key Statistics
A 2026 research article published in Acta Diabetologica found that indole propionic acid treatment activated the PI3K/Akt/GLUT4 signaling pathway in diabetic rats, improving their glucose metabolism and antioxidant defense systems.
Research reviewed by Gram showed that indole propionic acid, a metabolite produced by gut bacteria, enhanced cellular glucose uptake and reduced oxidative stress in a rat model of high-fat diet and streptozotocin-induced diabetes.
A 2026 study demonstrated that indole propionic acid improved multiple aspects of glucose metabolism simultaneously, suggesting the compound works through multiple biological pathways rather than a single mechanism.
The Quick Take
- What they studied: Whether a compound made by gut bacteria called indole propionic acid could improve blood sugar control and reduce damage in diabetic rats
- Who participated: Laboratory rats with diabetes induced by a high-fat diet and a chemical called streptozotocin, which mimics type 2 diabetes in humans
- Key finding: Indole propionic acid improved glucose metabolism, strengthened the body’s antioxidant defenses, and activated cellular pathways responsible for glucose uptake
- What it means for you: This research suggests that promoting beneficial gut bacteria that produce IPA might become a complementary diabetes management strategy, though human studies are needed before clinical recommendations can be made
The Research Details
This was a laboratory-based research study using animal models to understand how a specific gut bacterial metabolite affects diabetes. Researchers created diabetes in rats using a combination of a high-fat diet and streptozotocin, a chemical that damages insulin-producing cells. They then treated some diabetic rats with indole propionic acid while others served as controls. The researchers measured multiple outcomes including blood glucose levels, antioxidant enzyme activity, and the activation of specific cellular signaling pathways involved in glucose metabolism.
The study focused on the PI3K/Akt/GLUT4 signaling pathway, which is the cellular communication system that tells cells to absorb glucose from the bloodstream. By examining this pathway, researchers could understand the mechanism by which IPA might improve glucose control. This approach allowed them to identify not just whether IPA worked, but how it worked at the cellular level.
Understanding the mechanisms behind how gut bacteria influence diabetes is important because it could lead to new treatment strategies that work alongside insulin and other medications. Rather than just treating symptoms, targeting the gut microbiome addresses an underlying factor in metabolic disease. This research helps explain why some people with similar diets and lifestyles have different diabetes outcomes—their gut bacteria composition may differ significantly.
This is a preclinical animal study, which means it demonstrates proof-of-concept but cannot be directly applied to humans yet. Animal models are valuable for understanding biological mechanisms before investing in expensive human trials. The study’s publication in a peer-reviewed journal indicates it met scientific standards for methodology and reporting. However, results from rat studies often don’t translate directly to humans due to differences in metabolism and physiology. The correction notation suggests the authors made important clarifications to their original findings, which is a normal part of scientific publishing.
What the Results Show
Indole propionic acid treatment improved glucose metabolism in diabetic rats, meaning their bodies could process and use blood sugar more effectively. The compound enhanced the activity of antioxidant enzymes, which are the body’s natural defense system against cellular damage caused by high blood sugar. Most importantly, IPA activated the PI3K/Akt/GLUT4 signaling pathway, which is the cellular mechanism that allows glucose to enter cells from the bloodstream.
These findings suggest that IPA works through multiple pathways simultaneously. It doesn’t just lower blood sugar through one mechanism—instead, it addresses several problems that occur in diabetes: poor glucose uptake by cells, oxidative stress (cellular damage from reactive molecules), and impaired metabolic signaling. This multi-pronged approach is why researchers believe IPA could be therapeutically valuable.
The study demonstrated that IPA’s benefits extended beyond just glucose control. The compound appeared to restore normal cellular signaling that becomes disrupted in diabetes. This suggests IPA might help prevent some of the long-term complications of diabetes that result from sustained high blood sugar and oxidative stress. The activation of the GLUT4 glucose transporter is particularly significant because GLUT4 is the primary mechanism by which muscle and fat cells take up glucose in response to insulin.
Previous research has identified indole propionic acid as a beneficial metabolite produced by certain gut bacteria, but this study is among the first to specifically examine its therapeutic potential in diabetes. Earlier work suggested that people with diabetes have different gut bacterial compositions than healthy individuals, and this research provides a potential explanation for why—they may produce less IPA. The findings align with growing evidence that the gut microbiome plays a crucial role in metabolic health and diabetes development.
This study used laboratory rats, not humans, so results cannot be automatically applied to people with diabetes. Rats metabolize compounds differently than humans, and their physiology differs in important ways. The study did not examine whether oral IPA supplementation would be effective in humans or how it would be absorbed and processed. Additionally, the sample size and specific experimental details were not fully specified in the available information, which limits assessment of statistical power. Future human clinical trials would be necessary to determine if IPA supplementation or dietary strategies to increase IPA-producing bacteria could benefit people with diabetes.
The Bottom Line
Based on this preclinical research, people with diabetes should not yet consider IPA supplementation as a treatment, as human studies have not been conducted. However, the findings support general recommendations to maintain a healthy gut microbiome through dietary fiber, fermented foods, and diverse plant-based foods, which naturally support beneficial bacteria. Moderate confidence: Continue working with healthcare providers on established diabetes management strategies while staying informed about emerging microbiome research.
People with type 2 diabetes or those at risk for diabetes should find this research interesting as it points toward future treatment options. Researchers studying metabolic disease and the microbiome should prioritize human studies to test these findings. Healthcare providers managing diabetes should be aware of this emerging research direction. People should not change their diabetes management based on this animal study alone.
If human clinical trials begin soon, it could take 3-5 years to determine whether IPA supplementation is safe and effective in people. Even if successful, regulatory approval and clinical implementation could take several additional years. In the near term, people can support their gut microbiome through diet while waiting for human research results.
Frequently Asked Questions
Can I take indole propionic acid supplements to help with my diabetes?
Not yet based on current evidence. This research was conducted in rats, not humans. Before IPA supplements could be recommended for diabetes, human clinical trials would need to demonstrate safety and effectiveness. Consult your doctor before trying any new supplements.
What foods help my gut bacteria produce more indole propionic acid?
Foods high in fiber and plant compounds support bacteria that produce IPA, including whole grains, legumes, vegetables, fruits, and fermented foods like yogurt and sauerkraut. A diverse diet with 25-30 grams of daily fiber optimizes your microbiome.
How does gut bacteria affect blood sugar control?
Gut bacteria produce metabolites like indole propionic acid that influence how your body processes glucose and manages inflammation. Different bacterial compositions affect insulin sensitivity and glucose metabolism, which is why microbiome health impacts diabetes risk and control.
Is this rat study relevant to human diabetes treatment?
This study provides valuable proof-of-concept that IPA may help with diabetes, but animal studies don’t always translate to humans. The findings justify further research in humans, but shouldn’t change current diabetes management until human trials confirm the results.
What should I do differently based on this research?
Focus on established diabetes management: medication adherence, regular exercise, balanced nutrition, and stress management. Support your gut health through fiber-rich foods and diverse plant-based diet. Stay informed about microbiome research, but wait for human studies before trying new supplements.
Want to Apply This Research?
- Track daily fiber intake and gut health markers (bloating, digestion regularity) alongside blood glucose readings to monitor how dietary changes affecting the microbiome correlate with blood sugar patterns
- Increase consumption of prebiotic foods (garlic, onions, asparagus, bananas) and fiber-rich foods that feed beneficial gut bacteria, while logging these foods in the app to identify patterns with glucose control
- Create a 12-week tracking protocol measuring weekly average blood glucose, daily fiber intake, and digestive health symptoms to establish personal baseline and identify whether microbiome-supporting dietary changes correlate with improved glucose management
This article discusses preclinical research conducted in laboratory animals. The findings have not been tested in humans and should not be used to guide personal diabetes management decisions. Indole propionic acid is not currently approved as a diabetes treatment. People with diabetes should continue following their healthcare provider’s treatment recommendations and consult their doctor before making any changes to their diabetes management plan or trying new supplements. This research represents an early-stage investigation into potential future treatments and should not replace established medical care.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.